Cyclacel Pharmaceuticals Stock Forecast, Price & News

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

Is Cyclacel Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Cyclacel Pharmaceuticals?

Wall Street analysts have given Cyclacel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclacel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Cyclacel Pharmaceuticals.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings data on Tuesday, August, 10th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.09.
View Cyclacel Pharmaceuticals' earnings history.

How has Cyclacel Pharmaceuticals' stock price been impacted by COVID-19?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYCC shares have increased by 892.8% and is now trading at $5.36.
View which stocks have been most impacted by COVID-19.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on the morning of Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CYCC?

1 equities research analysts have issued twelve-month price targets for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 217.2% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:

• Spiro Rombotis, President, Chief Executive Officer & Director
• Paul McBarron, Secretary, Chief Operating & Financial Officer
• Mark Kirschbaum, Chief Medical Officer & Senior Vice President
• Amartya Basu, Senior Director-Business Development

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Some companies that are related to Cyclacel Pharmaceuticals include Sesen Bio (SESN), TFF Pharmaceuticals (TFFP), Corvus Pharmaceuticals (CRVS), Atreca (BCEL), Galectin Therapeutics (GALT), iBio (IBIO), Sol-Gel Technologies (SLGL), Impel NeuroPharma (IMPL), Flora Growth (FLGC), Oncternal Therapeutics (ONCT), CorMedix (CRMD), MediciNova (MNOV), PhaseBio Pharmaceuticals (PHAS), Trevena (TRVN) and Decibel Therapeutics (DBTX).
View all of CYCC's competitors.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.16%).
View institutional ownership trends for Cyclacel Pharmaceuticals.

Which institutional investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $5.36.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals has a market capitalization of $49.49 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-8.44 million in net income (profit) each year or ($3.87) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

Cyclacel Pharmaceuticals employs 2,018 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

Where are Cyclacel Pharmaceuticals' headquarters?

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at (908) 517-7330 or via email at [email protected].